Ticker Details
CytomX Therapeutics, Inc. CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform.
IPO Date:	October 8, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$788.08M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.26 | 3.53%
Avg Daily Range (30 D):	$0.09 | 2.61%
Avg Daily Range (90 D):	$0.16 | 3.77%

Institutional Daily Volume
Avg Daily Volume:	1.14M
Avg Daily Volume (30 D):	3.74M
Avg Daily Volume (90 D):	5.42M

Trade Size
Avg Trade Size (Sh.):	196
Avg Trade Size (Sh.) (30 D):	194
Avg Trade Size (Sh.) (90 D):	182

Institutional Trades
Total Institutional Trades:	1,246
Avg Institutional Trade:	$1.62M
Avg Institutional Trade (30 D):	$3.1M
Avg Institutional Trade (90 D):	$2.41M
Avg Institutional Trade Volume:	.28M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.84M
Avg Closing Trade (30 D):	$3.82M
Avg Closing Trade (90 D):	$2.93M
Avg Closing Volume:	308.13K

News

Jun 3, 2026 @ 12:00 PM CytomX Announces Expansion of Strategic Research C... Source: Na

May 21, 2026 @ 12:00 PM CytomX Therapeutics to Present at Upcoming June In... Source: Not Specified

Apr 22, 2026 @ 10:28 PM Small Cap or Megacap: Which Healthcare Stock Is Ri... Source: Jack Delaney

Mar 18, 2026 @ 2:46 AM CytomX Therapeutics Announces Pricing of $250 Mill... Source: Cytomx Therapeutics, Inc.

Feb 4, 2026 @ 1:00 PM CytomX Therapeutics to Present at Upcoming Februar... Source: Not Specified

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS
Diluted EPS
Revenue	$35.54M	$10.26M	$.66M
Gross Profit
Net Income / Loss	$-59.14M	$-18.25M	$-26.51M
Operating Income / Loss	$-64.66M	$-19.67M	$-27.93M
Cost of Revenue
Net Cash Flow	$-8.72M	$16.16M	$-21.02M
PE Ratio